on Gb Sciences (NASDAQ:GBLX)
GB Sciences Secures Licensing Deal with EndoPure Life Sciences
GB Sciences, a biopharmaceutical firm, announced an exclusive licensing agreement with EndoPure Life Sciences to introduce a cannabinoid-based Parkinson's treatment across Brazil and South America. EndoPure will finance the initial clinical trials, aiming to promote expansive distribution of GB Sciences' therapies.
This partnership will enable the marketing of GB Sciences' neurological products under the EndoPure brand, utilizing patient-friendly delivery methods, such as Oral Dissolving Tablets. CEO Allen Voigt highlighted the benefit for Parkinson's patients in these regions as GB Sciences' scientific validations back the treatment.
Dr. Andrea Small-Howard of GB Sciences emphasized that the deal not only secures a 5% royalty on gross sales but also facilitates potential U.S. FDA approval through data collected from these clinical trials.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Gb Sciences news